PATENT CLAIM ANALYSIS

Application Number: 15926407
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "170000"]

Abstract:
A method for contraception includes administering to a female daily, during a time period of 21 successive days, an oral combination drug formulation of norethindrone acetate and ethinyl estradiol (EE), wherein the drug formulation is administered in a biphasic dosing regimen comprising a 14 day phase and a 7 day phase, wherein doses of each of the norethindrone acetate and EE in the second phase of the regimen increase by a predefined dose increment as compared to the corresponding doses of the norethindrone acetate and EE administered during the first phase of the regimen, wherein the norethindrone acetate dose in the first phase is 1000 mcg and in the second phase is 1500 mcg, wherein the EE dose in the first phase is 20 mcg and in the second phase is 30 mcg, and wherein the biphasic dosing regimen is followed by 7 days without norethindrone acetate and EE administration.

Claim (Index 1):
A method of contraception in a female, comprising:\n administering to the female daily, during a time period of 21 successive days, an oral combination drug formulation of a progestin and an estrogen, wherein the oral combination drug formulation is administered in a biphasic dosing regimen comprising two phases, wherein the duration of one phase is 14 days and the duration of another phase is 7 days, wherein doses of each of the progestin and estrogen in the second phase of the regimen increase by a predefined dose increment as compared to the corresponding doses of the progestin and estrogen administered during the first phase of the regimen, wherein the ratio of a daily dose of progestin to a daily dose of estrogen is maintained at a constant level during the entire dosing period, wherein the progestin in the oral combination drug formulation is norethindrone acetate, wherein the norethindrone acetate dose in the first phase is 1000 mcg, wherein the norethindrone acetate dose in the second phase is 1500 mcg, wherein the estrogen in the oral combination drug formulation is ethinyl estradiol (EE), wherein the EE dose in the first phase is 20 mcg, wherein the EE dose in the second phase is 30 mcg and wherein the biphasic dosing regimen is followed by a time period of 7 days without progestin and estrogen administration.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 90.0
- Lexical Diversity: 2.46154
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14301768', '15593771', '08115008', '08462703', '12534902']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7786451982916607
- 35 USC 102 Novelty (BERT): 0.6905240168599229
- Combined Prediction Score: 0.7698330801484868
- Mean Citation Score: 505.94129600000014
- Max Citation Score: 698.2487
- Similarity Product: 691.0111792498351

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test